Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Use of Licensee's proprietary delivery formulation containing synthetic peptides of the CEA antigen (or modifications, derivatives, fragments, or immunogenic epitopes thereof) as claimed in the Licensed Patent Rights, alone or in combination with at least one other synthetic peptide for use in the prevention and/or treatment of adenocarcinomas in humans. For the avoidance of doubt, said delivery formulation specifically excludes all poxviruses, eukaryotic expression vectors, and recombinant yeast Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 9, 2007 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Technologies Relating to SH2 Domain Binding Inhibitors and Inhibition of Cell Motility and Angiogenesis Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 29, 2007 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: The Catalytic Moiety of the Glucose-6-Phosphatase System: The Gene and Protein and Related Mutations Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 29, 2007 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Use of Recombinant Yeast Expressing CEA for the Prevention and Treatment of Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 27, 2007 will be considered.
View Prospective Grant of Exclusive License: The Use of Adenovirus Vectors for the Development of Vaccines Against Human Immunodeficiency Virus and Other Infectious Agents Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 23, 2007 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Field of Use: Development of a Live Microbicide for Preventing Sexual Transmission of HIV Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before April 16, 2007 will be considered.
View Prospective Grant of Co-Exclusive License 10/14/2005.
View Government-Owned Inventions; Availability for Licensing